House dust mite allergen-IgE-T-cell receptor complex (HDM-IgE-TCR)

The House dust mite (HDM) allergen-IgE-T-cell receptor complex is a multi-component molecular system that mediates the allergic immune response to Dermatophagoides species, such as D. pteronyssinus and D. farinae. This system involves the interaction between major HDM allergens (e.g., Der p 1, Der p 2, and Der p 23), allergen-specific Immunoglobulin E (IgE) antibodies produced by sensitized patients, and T-cell receptors (TCRs) on CD4+ T-helper 2 (Th2) cells [1.2.1, 1.2.2]. In the sensitization phase, HDM allergens are processed by antigen-presenting cells and presented via MHC class II molecules to TCRs, promoting a Th2-biased environment and the production of allergen-specific IgE [1.2.3, 1.3.1]. Upon re-exposure, these allergens cross-link IgE bound to high-affinity receptors (FcεRI) on mast cells and basophils, leading to the release of inflammatory mediators like histamine and leukotrienes, which cause symptoms of asthma and allergic rhinitis [1.1.5, 1.3.2]. Therapeutic interventions targeting this axis include the use of standardized house dust mite allergen extracts (e.g., Odactra, Acarizax) for sublingual or subcutaneous immunotherapy, which aims to desensitize the patient by inducing IgG4 antibodies and T-cell anergy [1.1.5, 1.3.2]. Additionally, monoclonal antibodies such as omalizumab target the IgE component of this complex, effectively reducing the available pool of antibodies capable of triggering mast cell degranulation [1.1.1]. Emerging therapies also explore peptide-based vaccines designed to specifically target the TCR-allergen-MHC interaction to induce tolerance without the risk of IgE-mediated anaphylaxis [1.3.4].

Other names

House dust mite allergens – patient IgE and T-cell receptorsHDM allergen-IgE-TCR interactionHouse dust mite sensitization pathwayHDM-specific immune response

The primary mechanisms of action for drugs targeting this complex include IgE neutralization, which prevents the binding of allergen-specific IgE to FcεRI on effector cells, and allergen-specific immunotherapy (AIT), which induces immune tolerance through the expansion of regulatory T-cells (Tregs), production of blocking IgG4 antibodies, and induction of T-cell anergy or deletion.